BELLEVUE, WA / ACCESSWIRE / August 1, 2023 / Bellevue, Washington-based mental wellness center THIRA Health is excited to announce the launch of its Adolescent Residential Treatment Program that aims to help 13- to 17-year-olds struggling with anxiety, depression, and self-harm and trauma-related disorders.
The adolescent residential treatment program is built upon creative, innovative, and actionable ways of navigating treatment. With a team of experienced practitioners, this program offers round-the-clock guidance on DBT (Dialectical Behaviour Therapy) onboarding to support participants on their journey as they build coping skills that can cultivate long-term, meaningful life changes.
The program also includes a series of unique support such as:
For more information about the program, go to https://www.thirahealth.com/rtc-housing.
About THIRA Health
THIRA Health is led by a team of experts with collective experience exceeding 100 years and a dedication to helping people strive for a life worth living. Dr. Mehri Moore is our founder and Dr. Kathryn Korslund is our CEO – both doctors guide a team of 100+ clinical and support staff.
THIRA Health provides services ranging from residential for adolescents to intensive outpatient for ages 13+. Our commitment to the rigor of Dialectical Behaviour Therapy combined with innovative supportive treatments and medication management ensures top-tier treatment for women, teen girls and gender non-conforming individuals.
Contact Information
Sarah Skoterro
Director of Business Development
sarahs@thirahealth.com
206-718-0866
SOURCE: THIRA Health
View source version on accesswire.com:
https://www.accesswire.com/771375/THIRA-Health-Jump-Starts-Its-Adolescent-Residential-Treatment-Program
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…